Compared with metformin monotherapy, combination therapy achieved greater reductions in glycated hemoglobin (-1.8 ± 0.9% vs -1.3 ± 0.8%; P < .001), fasting and postprandial plasma glucose, fasting insulin, and homeostasis model assessment of insulin resistance. The gene discussed is INS; the disease is Insulin resistance.